These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16282390)

  • 21. Failing the public health--rofecoxib, Merck, and the FDA.
    Topol EJ
    N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193
    [No Abstract]   [Full Text] [Related]  

  • 22. A message from the Vioxx case.
    Baldwin HJ; Droege M; Daniel KL
    Am J Health Syst Pharm; 2006 Mar; 63(6):503. PubMed ID: 16522877
    [No Abstract]   [Full Text] [Related]  

  • 23. [Cardiovascular risk: a class effect of coxibs? How to manage patients taking Vioxx?].
    Brune K; Zacher J
    MMW Fortschr Med; 2004 Oct; 146(42):10, 12. PubMed ID: 15536697
    [No Abstract]   [Full Text] [Related]  

  • 24. Vioxx, the implosion of Merck, and aftershocks at the FDA.
    Horton R
    Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041
    [No Abstract]   [Full Text] [Related]  

  • 25. MI risk prompts rofecoxib withdrawal.
    Thompson CA
    Am J Health Syst Pharm; 2004 Nov; 61(21):2234-6, 2238. PubMed ID: 15552625
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
    Couzin J
    Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258
    [No Abstract]   [Full Text] [Related]  

  • 27. Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib).
    Carné X; Cruz N
    Eur J Epidemiol; 2005; 20(2):127-9. PubMed ID: 15792277
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug lawsuits building. Merck, Pfizer facing charges of misrepresentation.
    Benko LB
    Mod Healthc; 2006 Apr; 36(15):16. PubMed ID: 16669517
    [No Abstract]   [Full Text] [Related]  

  • 29. Merck appeals rofecoxib verdict.
    Tanne JH
    BMJ; 2007 Mar; 334(7594):607. PubMed ID: 17379897
    [No Abstract]   [Full Text] [Related]  

  • 30. Was Vioxx really that dangerous?
    Park A
    Time; 2005 Feb; 165(9):52. PubMed ID: 15765852
    [No Abstract]   [Full Text] [Related]  

  • 31. Balancing risks and benefits in pain medicine: wither Vioxx.
    Gallagher RM
    Pain Med; 2004 Dec; 5(4):329-30. PubMed ID: 15563316
    [No Abstract]   [Full Text] [Related]  

  • 32. What are the real lessons from Vioxx?
    Edwards IR
    Drug Saf; 2005; 28(8):651-8. PubMed ID: 16048352
    [No Abstract]   [Full Text] [Related]  

  • 33. How to avoid another 'Vioxx'.
    Frantz S
    Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
    [No Abstract]   [Full Text] [Related]  

  • 34. Discontinuation of Vioxx.
    Garattini S; Bertelé V
    Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671
    [No Abstract]   [Full Text] [Related]  

  • 35. Merck withdraws Vioxx; FDA issues public health advisory.
    FDA Consum; 2004; 38(6):11. PubMed ID: 15675020
    [No Abstract]   [Full Text] [Related]  

  • 36. Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx.
    Moynihan R
    BMJ; 2009 Apr; 338():b1432. PubMed ID: 19349350
    [No Abstract]   [Full Text] [Related]  

  • 37. The Vioxx debacle.
    Fielder JH
    IEEE Eng Med Biol Mag; 2005; 24(2):106-9. PubMed ID: 15825852
    [No Abstract]   [Full Text] [Related]  

  • 38. [Really only Vioxx?].
    Heinzl S
    Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229
    [No Abstract]   [Full Text] [Related]  

  • 39. The lessons of Vioxx.
    Frazier KC
    N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497
    [No Abstract]   [Full Text] [Related]  

  • 40. The politics of therapeutics.
    Somberg J
    Am J Ther; 2004; 11(6):422. PubMed ID: 15543080
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.